BioSpace News Archive

Immunomedics, Inc.(NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that it will host a conference call on Wednesday, October 30, 2019 at 5:00 p.m. Eastern Time to discuss financial results for the third quarter of 2019 and provide a corporate update.

Szilárd Kiss, M.D. to present an encore presentation of data from first cohort of the OPTIC phase 1 trial of ADVM-022 in wet AMD

BeyondSpring Inc. announced that the Company has enrolled its first patient in a Phase 3, Study 106, clinical trial with its lead asset, Plinabulin, for the prevention of chemotherapy-induced neutropenia Study 106 is enrolling patients receiving TAC chemotherapy plus Neulasta vs. TAC plus Plinabulin and Neulasta, to demonstrate Plinabulin’s exceptional ability to prevent CIN.

Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today announced that it has been invited to present at The Investor Summit (the “Conference”) on December 17, 2019 at Hotel Monaco in Philadelphia, Pennsylvania.

Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its third quarter 2019 financial results on Wednesday, October 30, 2019.

A poster presentation on the absence of impact due to acoustic trauma on the SENS-401 inner ear exposure in preclinical studies

Dr. Reddy’s Laboratories Ltd. confirms it had initiated a voluntary nationwide recall on October 1, 2019, of all of its ranitidine medications sold in US due to confirmed contamination with N-Nitrosodimethylamine above levels established by the FDA.

United Therapeutics Corporation announced that it will report its third quarter 2019 financial results before the market opens on Wednesday, October 30, 2019.

Viz.ai, the developer of the first synchronized healthcare software using artificial intelligence, announced a $50 million Series B funding.

Data from initial cohorts suggest that Arvinas’ PROTAC® platform has the potential to create safe and well-tolerated orally bioavailable drugs for the treatment of certain cancers